Patents by Inventor Joyce James

Joyce James has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
    Publication number: 20250134963
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Application
    Filed: November 11, 2024
    Publication date: May 1, 2025
    Applicant: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
    Patent number: 12171806
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: December 24, 2024
    Assignee: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
    Publication number: 20230104501
    Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 6, 2023
    Applicant: Spitfire Pharma LLC
    Inventors: Vyjayanthi Krishnan, Joyce James, Omar Roble Olhaye, Matthew Scott Harris
  • METHODS OF TREATING CNS TUMORS WITH TESETAXEL
    Publication number: 20210386720
    Abstract: The present disclosure provides methods for treating a patient with a cancer in the central nervous system, such as a cancer that is a metastasis of a primary cancer, comprising administering tesetaxel and capecitabine to the patient.
    Type: Application
    Filed: September 5, 2019
    Publication date: December 16, 2021
    Inventors: Joyce James, Kevin Tang, Stew Kroll, John G. Lemkey, Steven Pfeiffer, Jeff Vacirca, Thomas Wei
  • Treatment of enteral feeding intolerance
    Patent number: 10092621
    Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 9, 2018
    Assignee: Lyric Pharmaceuticals Inc.
    Inventors: David Wurtman, Joyce James, M. Scott Harris
  • TREATMENT OF ENTERAL FEEDING INTOLERANCE
    Publication number: 20170304395
    Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.
    Type: Application
    Filed: November 11, 2015
    Publication date: October 26, 2017
    Applicant: Lyric Pharmaceuticals Inc.
    Inventors: David Wurtman, Joyce James, M. Scott Harris